Systematic Review of Lung Cancer Screening: Advancements and Strategies for Implementation
- PMID: 37510525
- PMCID: PMC10379173
- DOI: 10.3390/healthcare11142085
Systematic Review of Lung Cancer Screening: Advancements and Strategies for Implementation
Abstract
Lung cancer is the leading cause of cancer-related deaths in Europe, with low survival rates primarily due to late-stage diagnosis. Early detection can significantly improve survival rates, but lung cancer screening is not currently implemented in Italy. Many countries have implemented lung cancer screening programs for high-risk populations, with studies showing a reduction in mortality. This review aimed to identify key areas for establishing a lung cancer screening program in Italy. A literature search was conducted in October 2022, using the PubMed and Scopus databases. Items of interest included updated evidence, approaches used in other countries, enrollment and eligibility criteria, models, cost-effectiveness studies, and smoking cessation programs. A literature search yielded 61 scientific papers, highlighting the effectiveness of low-dose computed tomography (LDCT) screening in reducing mortality among high-risk populations. The National Lung Screening Trial (NLST) in the United States demonstrated a 20% reduction in lung cancer mortality with LDCT, and other trials confirmed its potential to reduce mortality by up to 39% and detect early-stage cancers. However, false-positive results and associated harm were concerns. Economic evaluations generally supported the cost-effectiveness of LDCT screening, especially when combined with smoking cessation interventions for individuals aged 55 to 75 with a significant smoking history. Implementing a screening program in Italy requires the careful consideration of optimal strategies, population selection, result management, and the integration of smoking cessation. Resource limitations and tailored interventions for subpopulations with low-risk perception and non-adherence rates should be addressed with multidisciplinary expertise.
Keywords: cost-effectiveness; healthcare; low-dose computed tomography (LDCT); lung cancer; mortality reduction; screening program.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Systematic review of the cost-effectiveness of screening for lung cancer with low dose computed tomography.Lung Cancer. 2022 Aug;170:20-33. doi: 10.1016/j.lungcan.2022.05.005. Epub 2022 May 13. Lung Cancer. 2022. PMID: 35700629
-
Screening for Lung Cancer With Low-Dose Computed Tomography: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.JAMA. 2021 Mar 9;325(10):971-987. doi: 10.1001/jama.2021.0377. JAMA. 2021. PMID: 33687468
-
Estimating the Cost-Effectiveness of Lung Cancer Screening with Low-Dose Computed Tomography for High-Risk Smokers in Australia.J Thorac Oncol. 2018 Aug;13(8):1094-1105. doi: 10.1016/j.jtho.2018.04.006. Epub 2018 Apr 22. J Thorac Oncol. 2018. PMID: 29689434
-
Low-dose computed tomography lung cancer screening: Clinical evidence and implementation research.J Intern Med. 2022 Jul;292(1):68-80. doi: 10.1111/joim.13480. Epub 2022 Mar 24. J Intern Med. 2022. PMID: 35253286 Free PMC article. Review.
-
[Cost-effectiveness of lung cancer screening worldwide: a systematic review].Zhonghua Liu Xing Bing Xue Za Zhi. 2019 Feb 10;40(2):218-226. doi: 10.3760/cma.j.issn.0254-6450.2019.02.018. Zhonghua Liu Xing Bing Xue Za Zhi. 2019. PMID: 30744276 Chinese.
Cited by
-
The Saudi Thoracic Society Evidence-based guidelines for the diagnosis and management of chronic obstructive pulmonary disease.Ann Thorac Med. 2025 Jan-Mar;20(1):1-35. doi: 10.4103/atm.atm_155_24. Epub 2024 Sep 24. Ann Thorac Med. 2025. PMID: 39926399 Free PMC article.
-
Diagnostic value of miR-200 family in non-small cell lung cancer: a meta-analysis.Biomark Med. 2024;18(8):419-431. doi: 10.2217/bmm-2024-0087. Epub 2024 May 29. Biomark Med. 2024. PMID: 39041844 Free PMC article.
-
How will lung cancer screening and lung nodule management change the diagnostic and surgical lung cancer landscape?Eur Respir Rev. 2024 Jun 26;33(172):230232. doi: 10.1183/16000617.0232-2023. Print 2024 Apr. Eur Respir Rev. 2024. PMID: 38925794 Free PMC article. Review.
-
Impact of the COVID-19 pandemic on lung cancer screening utilization and outcome: a health examination center retrospective study.Ann Med. 2025 Dec;57(1):2525398. doi: 10.1080/07853890.2025.2525398. Epub 2025 Jun 28. Ann Med. 2025. PMID: 40580117 Free PMC article.
-
Protective effects of valencene, a natural sesquiterpene, against benzo(a)pyrene-induced lung cancer in Swiss albino mice.Med Oncol. 2025 Jul 30;42(9):393. doi: 10.1007/s12032-025-02962-4. Med Oncol. 2025. PMID: 40736625
References
-
- American Cancer Society Key Statistics for Lung Cancer. [(accessed on 8 May 2023)]. Available online: https://www.cancer.org/cancer/types/lung-cancer/about/key-statistics.html.
-
- Ferlay J., Ervik M., Lam F., Colombet M., Mery L., Piñeros M. Global Cancer Observatory: Cancer Today. [Updated 1 December 2020] [(accessed on 8 May 2023)]. Available online: https://gco.iarc.fr/today.
Publication types
LinkOut - more resources
Full Text Sources